Seattle Genetic is one of the fastest growing cancer drugs manufacturing company in the U.S. According to the CEO of the company, Clay Siegall, the company has been hiring over a 100 employees annually for the last five years. This means that the company has been performing well in the market. Just recently, the Vice President of United States, Joe Biden visited the Bethel- based company after hearing its reputations, Settle Genetics is targeting to employ more staff to work for the company and also manufacture more drugs apart from the single cancer drug. The move will positively impact the company on growth and development.
Adcetris is the only drug that is produced by the company. Currently, the company is working on marketing the drug and commercializing the drug for use in more cancer-related scenarios. The tests have shown positive results. Adcetris is widely used to cure lymphomas. Last year, the company made sales of 226 million dollars from the drug in both Canada and the United States.
Seattle Genetics primary focus is to provide drugs that will help cancer patients to slow down the spread of the disease, and the company has a goal to heal the disease. Adcetris is the only drug that is in the market; other drugs are in development and testing process. Seattle Genetics has twelve other drugs, which are expected to hit the market soon. These drugs include 33A, which are aiming to treat myeloid leukemia, a drug to treat bladder cancer and breast cancer among others.
Clay B. Siegall, Ph. D is the co-founder and the current CEO of Seattle Genetics. It was founded in 1998, and since that time Siegall Clay has been serving as one of the board member and the CEO. Under his leadership, the company has some achievements, and it has a rapid growth. It has managed to make over $300 since it was founded. Siegall’s career as the head of the company has been a success since it was started.